Cargando…
A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy
Chimeric antigen receptor T cell (CAR-T) therapy has been shown to be an effective strategy for combatting non-solid tumors; however, CAR-T therapy is still a challenge for solid tumors, such as glioblastoma. To improve CAR-T therapy for glioblastoma, a new TanCAR, comprising the tandem arrangement...
Autores principales: | Muhammad, Niaz, Wang, Rong, Li, Wenyan, Zhang, Zihan, Chang, Yongxing, Hu, Yitao, Zhao, Junli, Zheng, Xiaojing, Mao, Qinwen, Xia, Haibin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908045/ https://www.ncbi.nlm.nih.gov/pubmed/35317513 http://dx.doi.org/10.1016/j.omto.2022.02.012 |
Ejemplares similares
-
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013) -
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
por: Yi, Zhongzhen, et al.
Publicado: (2018) -
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
por: Hatano, Manabu, et al.
Publicado: (2004) -
Targeting EphA2 in cancer
por: Xiao, Ta, et al.
Publicado: (2020) -
The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size
por: Zapata-Mercado, Elmer, et al.
Publicado: (2022)